Five vaccine policy moves RFK Jr. could make
If he’s confirmed as health secretary, Robert F. Kennedy Jr. will have broad authority to pursue an anti-vaccine agenda.
Today's Liberal News
By Lauren Gardner
Bill Nye: RFK Jr. has ‘lost his way’
“Science Guy” takes nominee to head HHS to task over fluoride in drinking water.
Bill Nye: RFK Jr. has ‘lost his way’
“Science Guy” takes nominee to head HHS to task over fluoride in drinking water.
Bill Nye: RFK Jr. has ‘lost his way’
“Science Guy” takes nominee to head HHS to task over fluoride in drinking water.
Bill Nye: RFK Jr. has ‘lost his way’
“Science Guy” takes nominee to head HHS to task over fluoride in drinking water.
Bill Nye: RFK Jr. has ‘lost his way’
“Science Guy” takes nominee to head HHS to task over fluoride in drinking water.
Bill Nye: RFK Jr. has ‘lost his way’
“Science Guy” takes nominee to head HHS to task over fluoride in drinking water.
Biogen to cease production of controversial Alzheimer’s drug
The drugmaker will discontinue development and marketing for Aduhelm, a landmark Alzheimer’s disease treatment.
Biogen to cease production of controversial Alzheimer’s drug
The drugmaker will discontinue development and marketing for Aduhelm, a landmark Alzheimer’s disease treatment.
Biogen to cease production of controversial Alzheimer’s drug
The drugmaker will discontinue development and marketing for Aduhelm, a landmark Alzheimer’s disease treatment.
Biogen to cease production of controversial Alzheimer’s drug
The drugmaker will discontinue development and marketing for Aduhelm, a landmark Alzheimer’s disease treatment.
Biogen to cease production of controversial Alzheimer’s drug
The drugmaker will discontinue development and marketing for Aduhelm, a landmark Alzheimer’s disease treatment.
Biogen to cease production of controversial Alzheimer’s drug
The drugmaker will discontinue development and marketing for Aduhelm, a landmark Alzheimer’s disease treatment.
Biogen to cease production of controversial Alzheimer’s drug
The drugmaker will discontinue development and marketing for Aduhelm, a landmark Alzheimer’s disease treatment.
Biogen to cease production of controversial Alzheimer’s drug
The drugmaker will discontinue development and marketing for Aduhelm, a landmark Alzheimer’s disease treatment.
Biogen to cease production of controversial Alzheimer’s drug
The drugmaker will discontinue development and marketing for Aduhelm, a landmark Alzheimer’s disease treatment.
Biogen to cease production of controversial Alzheimer’s drug
The drugmaker will discontinue development and marketing for Aduhelm, a landmark Alzheimer’s disease treatment.
Biogen to cease production of controversial Alzheimer’s drug
The drugmaker will discontinue development and marketing for Aduhelm, a landmark Alzheimer’s disease treatment.
Biogen to cease production of controversial Alzheimer’s drug
The drugmaker will discontinue development and marketing for Aduhelm, a landmark Alzheimer’s disease treatment.
Biogen to cease production of controversial Alzheimer’s drug
The drugmaker will discontinue development and marketing for Aduhelm, a landmark Alzheimer’s disease treatment.
Biogen to cease production of controversial Alzheimer’s drug
The drugmaker will discontinue development and marketing for Aduhelm, a landmark Alzheimer’s disease treatment.
Biogen to cease production of controversial Alzheimer’s drug
The drugmaker will discontinue development and marketing for Aduhelm, a landmark Alzheimer’s disease treatment.
Biogen to cease production of controversial Alzheimer’s drug
The drugmaker will discontinue development and marketing for Aduhelm, a landmark Alzheimer’s disease treatment.
Biogen to cease production of controversial Alzheimer’s drug
The drugmaker will discontinue development and marketing for Aduhelm, a landmark Alzheimer’s disease treatment.
Biogen to cease production of controversial Alzheimer’s drug
The drugmaker will discontinue development and marketing for Aduhelm, a landmark Alzheimer’s disease treatment.
Court denies bid to halt Medicare drug price talks
The decision preserves the Biden administration’s power to begin haggling with drug companies over the prices of 10 medications.
Court denies bid to halt Medicare drug price talks
The decision preserves the Biden administration’s power to begin haggling with drug companies over the prices of 10 medications.
Court denies bid to halt Medicare drug price talks
The decision preserves the Biden administration’s power to begin haggling with drug companies over the prices of 10 medications.
Court denies bid to halt Medicare drug price talks
The decision preserves the Biden administration’s power to begin haggling with drug companies over the prices of 10 medications.
Court denies bid to halt Medicare drug price talks
The decision preserves the Biden administration’s power to begin haggling with drug companies over the prices of 10 medications.